FDA 483s and Responses available in the World Wide Web
Recommendation

27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
The Freedom of Information Act (FOIA) allows anyone to request copies of records that are normally not fully prepared for public distribution. According to the Act, materials and other information have to be available in publicly accessible "electronic reading rooms" with systems that also allow users to electronically search for files and index materials.
However, not everybody interested in certain documents has the time and possibility to visit these public reading rooms. But the Office of Regulatory Affairs (ORA) Electronic Reading Room also displays copies of certain records in the World Wide Web. ORA is making these records publicly available either proactively at ORA's discretion or because they are "frequently requested" per the Electronic Freedom of Information Act Amendments from 1996.
Under the URL of the ORA FOIA Electronic Reading Room, everyone can review 483s*, 483 responses, Consent Decree Correspondence** and other interesting documents. These may also provide information on what the FDA expects - helping companies to prepare for an inspection by the agency.
*483 is the number of a form used by an FDA Investigator to document the deficiencies he found during an inspection. It is issued at the end of the inspection and should be answered officially. This response is expected within 15 working days after its issuance. Only then it is guaranteed that the statement will be taken into account in a possible Warning Letter.
**If a company has repeatedly violated cGMP requirements, FDA may make a legal agreement to force the company to take specific actions. A Consent Decree can include penalties and due dates for the actions defined. Sometimes a consulting company will check the company and streamline systems and processes. A final inspection is carried out at the end. In the meantime, profits can be skimmed off.
Related GMP News
27.04.2026FDA remains active in Europe - further Inspections despite MRAs
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight


